首款侵入式脑机接口医疗器械国内获批，产业融资热度持续

Investment Rating - The report maintains an investment rating of "Leading the Market" for the medical device industry, indicating that the industry index is expected to outperform the CSI 300 index by more than 5% [3][8]. Core Insights - The brain-computer interface (BCI) sector is included in the "14th Five-Year Plan" as one of the six future industries requiring proactive layout, signaling a period of intensive policy support and technological advancement [6]. - The first domestically approved invasive brain-computer interface medical device, developed by Borui Kang, has been launched, marking a significant breakthrough in clinical applications for patients with quadriplegia due to cervical spinal cord injuries [6]. - The capital market remains active, with Ladder Medical completing a strategic financing round of 500 million yuan, which will accelerate its clinical progress in the BCI field [6]. - The report suggests that the medical device industry is poised for multidimensional development driven by technological platformization, AI diagnostics, and consumer healthcare expansion, with a focus on high-quality growth and long-term investment opportunities [6]. Summary by Sections Policy Insights - The BCI technology is now recognized at the national strategic level, with key technological advancements in hardware, algorithms, and databases being prioritized for development [6]. Application Developments - Borui Kang's BCI device consists of several components, including an implanted brain-computer interface, electrodes, and software, which have shown significant improvements in hand function for patients during clinical trials [6]. Market Activity - Ladder Medical's recent financing round led by Alibaba and other investors highlights the ongoing interest and investment in the BCI sector, with plans for large-scale clinical trials in 2026 [6]. Investment Recommendations - The report emphasizes the potential for investment in the BCI industry, particularly in companies with advanced clinical progress and commercialization prospects, such as Aipeng Medical, Xiangyu Medical, and Kefu Medical [6].